Merck Reports P-III Trial (NRG-GY018) Results of Keytruda (pembrolizumab) as 1L Treatment for Advanced or Recurrent Endometrial Carcinoma
Shots:
- The P-III trial (NRG-GY018) evaluating Keytruda + CT vs PBO + CT alone in 819 patients with measurable stage III, IVA, IVB, or recurrent endometrial cancer in pMMR and dMMR cohorts. NCI sponsored the trial
- The trial met its 1EPs i.e., improvement in PFS at a pre-specified interim analysis. The safety profile was consistent with prior reported studies with no new safety signals & the results will be presented at an upcoming medical meeting & discussed with regulatory authorities
- The company has a comprehensive clinical development program in EC. Keytruda is being studied as monotx. (KEYNOTE-C93/ENGOT-en15/GOG-3064) & in combination with Lenvima (LEAP-001/ENGOT-en9) for 1L advanced EC along with adjuvant setting (KEYNOTE-B21/ENGOT-en11/GOG-3053)
Ref: Merck | Image: Merck
Related News:- Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Approval for the Treatment of Non-Small Cell Lung Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
